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Human UNG2 is a multifunctional glycosylase that re-
moves uracil near replication forks and in non-replicating
DNA, and is important for afﬁnity maturation of antibodies
in B cells. How these diverse functions are regulated
remains obscure. Here, we report three new phosphoforms
of the non-catalytic domain that confer distinct functional
properties to UNG2. These are apparently generated by
cyclin-dependent kinases through stepwise phosphoryla-
tion of S23, T60 and S64 in the cell cycle. Phosphorylation
of S23 in late G1/early S confers increased association with
replication protein A (RPA) and replicating chromatin
and markedly increases the catalytic turnover of UNG2.
Conversely, progressive phosphorylation of T60 and S64
throughout S phase mediates reduced binding to RPA and
ﬂag UNG2 for breakdown in G2 by forming a cyclin E/c-
myc-like phosphodegron. The enhanced catalytic turnover
of UNG2 p-S23 likely optimises the protein to excise uracil
along with rapidly moving replication forks. Our ﬁndings
may aid further studies of how UNG2 initiates mutagenic
rather than repair processing of activation-induced
deaminase-generated uracil at Ig loci in B cells.
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Introduction
Uracil is one of the most common base lesions in DNA and
may result from misincorporation of dUMP instead of dTMP
during replication or from deamination of cytosine (Kavli
et al, 2007). While U:A pairs generated from misincorpora-
tion of dUMP are not directly mutagenic, deamination of
cytosine results in mutagenic U:G mispairs. In most cells,
deamination occurs spontaneously. However in B cells, DNA
cytosine at Ig loci may also be enzymatically deaminated to
uracil by activation-induced deaminase (AID) (Rada et al,
2002; Dickerson et al, 2003). The importance of sanitation of
genomic uracil is indicated by the ubiquitous presence of
uracil DNA glycosylases (UDGs) (Krokan et al, 2000). In
humans, UNG2 constitutes the quantitatively dominating
UDG activity in the nucleus, and is the major enzyme for
removal of both misincorporated uracil and deaminated
cytosines (Kavli et al, 2002). Moreover, UNG2 is the only
known glycosylase involved in antibody diversiﬁcation, by
processing of AID-induced U:G pairs in B cells (Kavli et al,
2005; Di Noia et al, 2006). Finally, UNG2 appears to be
involved in the assembly of CENP-A at centromeres (Zeitlin
et al, 2005), although its precise role in this context remains
to be determined. Given the diverse roles of UNG2 in
mammalian nuclei and its ability to initiate either repair or
mutagenic processing of uracil, it is reasonable that the
protein is subject to precise regulation. At the transcriptional
level, two mRNAs are expressed from the UNG gene by the
use of different promoters and alternative splicing (Nilsen
et al, 1997; Haug et al, 1998). The UNG1 mRNA encodes a
304aa protein translocated to mitochondria, while the UNG2
mRNA encodes a 313aa protein that is translocated intact to
nuclei (Otterlei et al, 1998). Both mRNAs are cell cycle
regulated, reaching maximum levels just prior to the
S phase (Slupphaug et al, 1991; Haug et al, 1998). The
C-terminal 220 residues of UNG2 form a compact, globular
catalytic domain (Mol et al, 1995; Slupphaug et al, 1995,
1996), while the N-terminal region constitutes a distinct
regulatory domain that is not necessary for enzymatic activity
(Kavli et al, 2002). The 86aa N-terminal non-catalytic do-
main furthermore confers biochemical properties to UNG2
that are not displayed by the catalytic domain alone, includ-
ing a strong single-strand DNA preference of UNG2 in the
presence of physiological concentrations of Mg
2þ (Kavli et al,
2002), supporting a role for UNG2 in uracil removal from
ssDNA, for example, in front of the replicative polymerase
complex and in R-loops at Ig loci. A role for UNG2 in
processing of uracil in ssDNA is substantiated by the presence
of at least one replication protein A (RPA)-binding motif in
the UNG2 N-terminal domain. Furthermore, a PCNA-binding
motif located at the N terminus is likely important for the role
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51of UNG2 in rapid postreplicative removal of misincorporated
dUMP at the replication fork (Otterlei et al, 1999).
UNG2 is the initiating factor in uracil-BER in the nucleus,
as well as a central mediator in afﬁnity maturation of anti-
bodies. It is thus highly relevant to investigate to what extent
the non-catalytic domain modulates UNG2 function, and the
present work addresses the signiﬁcance of phosphorylation
in this context. It has previously been demonstrated that
UNG2 exists as a phosphoprotein in vivo (Muller-Weeks
et al, 1998) and that it apparently may be phosphorylated
at T6 and T126 subsequent to UV irradiation (Lu et al, 2004).
Here, we report three novel, major phosphorylation forms of
UNG2 present in freely cycling HeLa cells, and demonstrate
that these are regulated throughout the cell cycle. Combined
with functional analysis of phosphomimicking and phos-
phoinhibiting UNG2 mutants and activity analysis of true
UNG2 phosphoforms, our results support a model in which
the total cellular level, the activity and the association of
UNG2 with proteins at the replication fork are regulated
by three consecutive phosphorylations in the non-catalytic
N-terminal domain.
Results
UNG2 in freely cycling HeLa cells is stepwise
phosphorylated at three Ser/Thr residues in the
N-terminal non-catalytic domain
To identify potential UNG2 phosphoforms, UNG2 was pre-
cipitated from nuclear extracts of proliferating HeLa cells
using UNG antibody PU059. Captured proteins were separa-
ted by isoelectric focusing in the pI range 7–11 and subjected
to second dimension SDS–PAGE. Silver-stained spots in the
expected pI and MW range of UNG2 (Figure 1A) were excised
and subjected to trypsination and MALDI-TOF MS peptide
mass ﬁngerprinting. Four of the spots were identiﬁed as
UNG2 (forms 1–4; Figure 1A). The peptide ﬁngerprints
revealed mass shifts corresponding to one phosphate in
residues 20–49 (in forms 2–4), one phosphate in residues
51–73 (in form 3) and two phosphates in the latter peptide in
form 4. The presence of phosphates in forms 2–4 was further
veriﬁed by pretreatment of the immunoprecipitated UNG2
with calf intestine phosphatase prior to 2D PAGE and western
analysis. This resulted in loss of all UNG2 forms except the
most positively charged form 1 representing unphosphory-
lated UNG2 (Figure 1B).
To identify the phosphorylated residues more precisely,
peptides from the four spots were analysed by MALDI Q-TOF
MS/MS (Stensballe and Jensen, 2004) (Figure 2A–C). The
analyses revealed the following UNG2 isoforms: form 1:
unphosphorylated; form 2: monophosphorylated at S23;
form 3: double phosphorylated at S23 and T60 and form 4
triple phosphorylated at S23, T60 and S64. Moreover, the lack
of observed single phosphorylations at T60 and S64 suggests
that the phosphorylations occur in a stepwise fashion from
the N-terminus to the C-terminus of the regulatory domain.
The localisation of the phosphorylated residues within the
human UNG2 N-terminus is shown in Figure 2D together
with known N-terminal sequences from other eukaryotic
UNG2 proteins. The known PCNA- and RPA-binding regions
in hUNG2 are also illustrated. The MS/MS sequencing results
were entirely in agreement with the MALDI-TOF results
and were also conﬁrmed using the program DISPHOS 1.3
(http://core.ist.temple.edu/pred/information.html) using the
entries from the Phospho.ELM database (Diella et al, 2004).
This stringent predictor takes into consideration that intrinsic
structural disorder in and around the potential target is a
prerequisite for phosphorylation, and notably identiﬁes S23,
T60 and S64 in addition to S63 as potential phosphorylation
sites. These Ser/Thr residues are the most conserved in the
eukaryotic sequences outside the highly conserved PCNA-
and RPA-binding regions (Figure 2D).
Interestingly, the second and third phosphorylations (at
T60 and S64, respectively) create a motif that is very similar
to the phosphodegrons observed in cyclin E, c-Myc, c-Jun,
Notch1 and SREBP1 (Welcker and Clurman, 2007 and refer-
ences therein) that serves as recognition motifs for their
ubiquitinylation and proteasomal degradation subsequent to
phosphorylation (Figure 2D). To investigate whether this
apparent phosphodegron could be formed in vivo in the
absence of a phosphorylated S23 residue, UNG2-EYFP and
the phospho-negative mutant UNG2 S23A-EYFP were ex-
pressed in HeLa. 2D western analysis of total cell extracts
using GFP antibodies revealed increased accumulation of the
unphosphorylated proteins relative to that observed for en-
dogeneous UNG2 (Figure 2E). Moreover, WT UNG2-EYFP
appeared to harbour a fourth and not yet identiﬁed phos-
phorylation. Nevertheless, UNG2 S23A-EYFP lacked only one
of the phosphorylations observed in the unmutated protein,
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Figure 1 Isolation of UNG2 phosphoforms. (A) UNG2 was immuno-
precipitated from HeLa nuclear extract using PU059 antibodies
and separated by 2D PAGE (18cm IPG strip pH 7–11). Spots
representing UNG2 were identiﬁed by MALDI-TOF MS ﬁngerprint-
ing. Spot 1: unphosphorylated; spot 2: phosphorylated in peptide
20–49; spot 3: phosphorylated in peptides 20–49 and 50–73/51–73
(expected missed cleavage site) and spot 4: phosphorylated in
peptides 20–49 and doubly phosphorylated in peptides 50–73/51–
73 (B) 2D PAGE (7cm IPG strip pH 7–11) and western analysis of
immunoprecipitated UNG2 without phosphatase pretreatment (left
panel) and after phosphatase pretreatment (right panel).
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Figure 2 Characterisation of phosphorylation sites in UNG2 by MALDI Q-TOF MS/MS. (A) Spots 2–4 contain phosphate on Ser23. (B) Spot 3
contains phosphate on Thr60. (C) Spot 4 contains phosphates at both Thr60 and Ser64. (D) Alignment of N-terminal amino-acid sequences in
UNG2 from higher eukaryotes using ClustalX (Thompson et al, 1997). Individual residues are coloured according to ClustalX colour coding.
Highest degree of conservation is observed in the regions corresponding to the PCNA- and RPA-binding motifs of hUNG2. Among the serines
and threonines outside these motifs, S23, T60 and S64 are the most conserved. The boxed sequences in (D) illustrate phosphodegrons in other
human proteins, which share sequence homology to UNG2. (E) Phosphorylation of T60/S64 may occur in the absence of S23 phosphorylation.
WT UNG2 and UNG2 S23A were expressed as EYFP fusion proteins in HeLa cells, and different phosphoforms visualised subsequent to 2D
PAGE and western analysis using antibodies against EYFP.
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phosphorylation at the T60 and S64 positions.
Phosphorylation of UNG2 at S23, T60 and S64 is cell
cycle regulated and directs ubiquitinylation and
proteolytic breakdown in late S/G2
UNG2 is several fold upregulated during late G1 and early S
phases (Slupphaug et al, 1991; Haug et al, 1998; Fischer et al,
2004). To investigate whether the UNG2 phosphorylations
were also cell cycle regulated, HeLa cells were synchronised
at the G1/S border by double thymidine block, and analysed
at deﬁned time points after release. Analysis of total cellular
UNG2 by 1D PAGE and western analysis demonstrated max-
imum UNG2 protein in early S phase, while a pronounced
reduction at the protein level was observed in late S and G2
(Figure 3A). Moreover, separation of the proteins by 2D PAGE
revealed a marked shift in the relative amounts of each of
the UNG2 phosphoforms through the cell cycle (Figure 3B).
In early S (3h), the un- and monophosphorylated forms of
UNG2 dominate. Towards the end of S (6h), the relative
amount of the di- and triphosphorylated forms increases,
while in late G2 (9h) the latter forms dominate over the un-
and monophosphorylated forms. Entry into the next G1
(12h) is accompanied by reappearance of the un- and mono-
phosphorylated forms, and the cycle is repeated (15–21h).
The cell cycle data are summarised in Figure 3C. Notably, the
triphosphorylated form 4 increases in late S, and peaks in G2
concomitantly with the appearance of a ﬁfth form of UNG2
(marked with an asterisk in Figure 3B at 9h) of higher
molecular weight (HMW). Although the total UNG2 level in
the cells is very low in G2, this HMW form dominates in late
G2. The order of appearance of the HMW form suggests that
it is generated by further modiﬁcation of the triple-phos-
phorylated form 4. This is also supported by the migration
in 2D PAGE of the HMW form relative to the triple-phos-
phorylated form 4, corresponding to an MW and pI shift that
would be expected from a mono-ubiquitinylated form 4
UNG2. Ubiquitinylation of UNG2 has previously been re-
ported to induce proteasome-mediated degradation of
UNG2 in S phase (Fischer et al, 2004). To further analyse
the nature of the HMW form, western blots from 2D gels were
doubly labelled with polyclonal anti-UNG PU059 and mono-
clonal anti-ubiquitin antibodies prior to incubation with both
Cy3- and Cy5-labelled anti-mouse and anti-rabbit secondary
antibodies, respectively (Figure 3D). A strong signal was
obtained with both Cy3 and Cy5 over the HMW form of
UNG2, strongly supporting that this form is mono-ubiquiti-
nylated and triply phosphorylated UNG2. Notably, in contrast
to UNG2 forms 1–4, ubiquitinylated UNG2 could not be
immunoprecipitated from cell extracts using anti-UNG
PU059 antibodies. UNG2 was also not accessible when
ubiquitin was targeted for immunoprecipitation, indicating
that this form is unstable or transient in nature, or that
afﬁnity capture is hampered by ubiquitin or by other proteins
binding to UNG2.
The doubly phosphorylated pT380/pS384 degron in cyclin
E was recently demonstrated to be an optimal, high-afﬁnity
degron (Hao et al, 2007). To investigate whether the corre-
sponding sequence in UNG2 also constitutes a degron, UNG2
T60 and S64 were mutated to alanine, and expressed as EYFP
fusions in HeLa. The concentrations of the transfection con-
structs were reduced to avoid too high expression of the
fusion proteins and saturation of the UNG2 processing ma-
chinery. The cells were co-transfected with ECFP as an
internal standard to correct for potential differences in trans-
fection efﬁciency. Subsequent to western analysis of total cell
lysates using GFP antibodies, the Ala mutants were all
detectable at 2.5- to 3-fold higher levels compared to WT
UNG2 (Figure 3E). These results strongly indicate that the
sequence encompassing T60 and S64 in UNG2 constitutes a
phosphodegron.
Finally, to investigate whether speciﬁc phosphoforms of
UNG2 were poorly extracted by our procedure, pellets re-
maining after the ﬁrst extraction step were sonicated in high
salt buffer to release proteins strongly binding to chromatin.
This consistently revealed small amounts of unphosphory-
lated (form 1) and S23-phosphorylated (form 2) UNG2 that
were not extracted in buffer containing 200mM KCl
(Figure 3F, right panels). Moreover, which of these two
forms were most tightly associated with chromatin appeared
to be dependent on the cell cycle stage. Thus, outside the S
phase, unphosphorylated UNG2 was retained more in the
chromatin relative to UNG2 p-S23, while in S phase a more
selective binding of UNG2 p-S23 was observed (Figure 3F,
arrows). These results indicate that S23-phosphorylated
UNG2 has an increased afﬁnity for replicating chromatin
relative to the other UNG2 forms.
Phosphomimicking mutations in the UNG2 regulatory
domain modulate catalytic activity and association
with RPA
To analyse functional implications of the observed UNG2
phosphorylations, each of the phosphoforms were mimicked
by mutation of the corresponding Ser/Thr residues to Asp,
and puriﬁed to apparent homogeneity (S23A and S23A/
T60A/S64A were included as controls) (Figure 4A). The
ﬁrst attempts to purify the triple phosphomimicking UNG2
S23D/T60D/S64D as well as a UNG2 S64D mutant resulted in
catalytically impaired proteins. However, by reducing the
sonication energy during bacterial lysis, and performing all
steps during puriﬁcation on ice (including the Talon column
step), we obtained fully active proteins. These ﬁndings
indicate that a negative charge introduced at residue 64 in
the UNG2 N-terminus introduces a local structural instability
in the protein that may be of functional relevance, and further
studies are now underway to determine the overall structural
change in UNG2 following S64D mutation.
Interestingly, an overall increase in enzymatic activity was
observed with the phosphomimicking mutants relative to
WT, and the increase was most pronounced with ssDNA
substrate. The increase was less pronounced with the Ala
mutants, demonstrating that introduction of negative charges
at the distinct positions in the UNG2 regulatory domain
speciﬁcally stimulates the activity of UNG2. To analyse the
activity stimulation in more detail, the phosphomimicking
mutants were subjected to kinetic analyses. These analyses
revealed that the mutations had a mixed effect upon afﬁnity
(Km) and turnover (kcat) of UNG2 (Table I). In general, the
introduced negative charges mediated a marked increase in
the catalytic turnover against both types of substrate,
although also accompanied by a somewhat increased Km.
Notably, the single S23D mutation resembling the dominant
S-phase phosphoform of UNG2 increased the catalytic turn-
over about two- and three-fold relative to WTagainst dsDNA
Phosphorylation of human UNG2
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turnover could be of biological signiﬁcance to optimise uracil
excision at rapidly moving replication forks. Additional
mutation of T60 and S64 mediated somewhat reduced
catalytic turnover compared to the single S23D mutant. The
primary function of these phosphorylations is thus likely to
form a functional phosphodegron, although speciﬁc func-
tions in uracil processing cannot be excluded.
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Figure 3 Cell cycle regulation of UNG2 protein level and phosphorylation status. (A) HeLa cells were synchronised by double thymidine block
and whole-cell extracts prepared at the indicated time points after release and separated by 1D PAGE prior to western analysis using anti-UNG
PU059 and b-actin primary antibodies. (B) The same extracts as in (A) were subjected to 2D PAGE and western analysis using anti-UNG PU059
primary antibodies (left panels). FACS analyses of the cell cycle distribution at each time point are illustrated in the right panels. (C)
Quantitative distribution of the different UNG2 forms through the cell cycle. Since different 2D gels cannot be directly quantitatively compared,
the sum of all UNG2 forms at each time point is given relative to the sum of all forms at the time of release (100%) based on western
quantiﬁcation after 1D PAGE. The individual distribution of the UNG2 forms at each time point (each 2D gel) is based on western quantiﬁcation
after 2D PAGE. (D) 2D western analysis of HeLa whole-cell G2 extract using a mixture of PU059 and anti-ubiquitin primary antibodies and a
mixture of Cy3- and Cy5-labelled anti-mouse and anti-rabbit secondary antibodies. Green signal: UNG2; red signal: ubiquitin. The merged
image demonstrates ubiquitinylation of the HMW UNG2 form (asterisk). (E) Phosphoinhibiting (S/T-A) mutations in the putative UNG2
phosphodegron result in increased cellular accumulation of UNG2. HeLa cells were transfected with pUNG2-EYFP and phosphoinhibiting
mutants thereof in the putative phosphodegron. Co-transfection with equal amount of vector expressing ECFP was used as internal control to
monitor transfection efﬁciency. Expression of UNG2-EYFP proteins was quantiﬁed relative to ECFP subsequent to western analysis using anti-
EGFP antibodies (mean of two independent experiments). (F) UNG2 forms 1 and 2 extracted at 200mM KCl (left) and remaining in chromatin
(right). Arrows indicate that the association of UNG2 p-S23 (form 2) with chromatin is increased during S phase relative to unphosphorylated
UNG2 (form 1). Note that western images in the right panels were obtained by several fold longer exposure times compared to those in the left
panels.
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binding to PCNA and/or RPA, puriﬁed UNG2 proteins were
incubated with extracts from UNG-deﬁcient human B-cell
lines derived from hyper-IgM patients (Imai et al, 2003;
Kavli et al, 2005), immunoprecipitated using PU059 and
analysed for coprecipitation of PCNA and RPA. Binding of
UNG2 to PCNA was not markedly inﬂuenced by any of the
mutations (Figure 4B). This was also supported by activity
analyses of the UNG2 proteins in the presence of PCNA, in
which a two-fold stimulation of all the UNG2 forms was
observed (data not shown).
Conversely, the binding of UNG2 to RPAwas markedly and
differentially affected by the mutations (Figure 4C). Notably,
the S23D mutation mediated a moderate but consistent
increase in the binding of UNG2 to RPA in agreement with
preferential binding of monophosphorylated UNG2 P-S23 to
chromatin in S-phase cells (Figure 3F). A similar increase in
RPA binding of the S23A mutant suggests that alterations of
the local UNG2 secondary structure, rather than the speciﬁc
charge mediate increased binding. The additional T60D and
S64D mutations mediated progressive loss of RPA binding,
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Figure 4 Phosphomimicking mutations markedly affect UNG2 activity and binding to RPA. (A) Catalytic activity of UNG2 mutants relative to
WT measured against ssDNA (dark grey bars) and dsDNA (light grey bars) substrates. Each bar represents the mean of three experiments with
standard deviations as indicated. Lower panel illustrates the puriﬁed proteins after 1D PAGE and SimplyBlue staining. (B, C) WT UNG2 and
mutants were incubated with extracts from UNG-deﬁcient B cells and binding to PCNA (B) or RPA (C) quantiﬁed after UNG2 IP, 1D PAGE and
western analysis (lower panels). Each bar represents PCNA (or RPA) signal divided by UNG2 input signal, and averaged from six independent
experiments with standard deviations as indicated. (D) Phosphomimicking and phosphoinhibiting mutations do not affect localisation of UNG2
to replication foci. UNG2-EYFP WTand mutants were co-transfected in HeLa cells with PCNA-ECFP to verify localisation in replication foci.
Table I Kinetic constants of UNG2 and N-terminal UNG2 phospho-
mimicking mutants
Enzyme Substrate Km (mM) kcat (min
 1)
Without RPA
WT U:A 1.070.08 44979
S23D U:A 1.870.06 87076
S23D, T60D U:A 1.470.06 64176
S23D, T60D, S64D U:A 1.270.07 72675
WT Uss 0.0570.00 663710
S23D Uss 0.1470.01 1981713
S23D, T60D Uss 0.0970.01 1141715
S23D, T60D, S64D Uss 0.1170.01 1360710
With RPA
WT U:A 0.5970.09 14375
S23D U:A 0.7070.06 18777
S23D, T60D U:A 0.6670.06 16277
S23D, T60D, S64D U:A 0.6770.07 27276
WT Uss 0.0470.005 773718
S23D Uss 0.0570.004 1204711
S23D, T60D Uss 0.0370.004 546711
S23D, T60D, S64D Uss 0.0270.003 882710
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40% of the RPA-binding capacity relative to WT UNG2.
Importantly, a corresponding loss was not observed with
the triple Ala mutant, indicating that the negative charge in
the putative phosphodegron mediates reduced RPA binding.
In the solution NMR structure of the UNG2 peptide encom-
passing residues 73–88 bound to the RPA32 subunit (Mer
et al, 2000), the UNG2 peptide adopts a helical structure upon
binding to RPA32. Here, interaction of three arginines in
UNG2 with four acidic residues in RPA32 contributes to the
binding. Our results indicate that the region of UNG2 encom-
passing residues T60 and S64 may also contact RPA32,
and that phosphorylation of these residues may contribute
repulsive forces between the two proteins.
Given the high local concentration and crucial importance
of RPA near the replication fork (reviewed in Fanning et al,
2006), the above ﬁndings prompted us to investigate if the
presence of RPA modulated the kinetic properties of the
UNG2 proteins. Whereas RPA stimulated catalytic turnover
of WT UNG2 turnover against ssDNA substrate, the three
phosphomimicking mutants displayed reduced turnover
(Table I). Nevertheless, the S23D mutant still maintained
the highest turnover among the four proteins. Conversely,
RPA mediated a larger increase in the afﬁnity (lowered Km)o f
the phosphomimicking mutants against ssDNA substrate,
compared to WT.
Given the markedly reduced binding of UNG2 S23D/T60D/
S64D to RPA, we wanted to investigate whether the phos-
phorylation status of UNG2 affected its localisation to repli-
cation foci. WT UNG2, phosphomimicking mutants as well
as phosphoinhibiting (Ala) mutants were thus transiently
expressed in HeLa cells as EYFP fusion proteins together
with ECFP-PCNA (Figure 4D). The intracellular localisation
of UNG2-EYFP, UNG2 S23D/T60D/S64D-EYFP and UNG2
S23A/T60A/S64A-EYFP together with ECFP-PCNA is illu-
strated in Figure 4D. Notably, the subcellular localisation
of the mutants in replication foci was not altered compared
to WT UNG2. Identical results were obtained subsequent to
transfection with single (S23) and double (S23/T60) mutants
to Asp/Ala (data not shown). Thus, the overall localisation
of UNG2 to nuclei and replication foci is apparently not
directly controlled by cell cycle-regulated N-terminal
phosphorylations. This is in accordance with the fully com-
petent PCNA binding of the phosphomimicking mutants
(Figure 4B), which likely contributes to their localisation
in replication foci. No overt reduction in the overall level
of the triple phosphomimicking mutant could be observed.
However, this likely reﬂects that under conditions of
overexpression, the speciﬁc ubiquitinylation apparatus
becomes saturated. Alternatively, phosphomimicking mu-
tants cannot directly substitute phosphoserines or phos-
phothreonines in the contact of the docking site to the
ubiquitin ligase.
Finally, it should be mentioned that we have not been able
to produce stably transfected HeLa cell lines producing UNG2
under the strong CMV promoter, whereas we have success-
fully produced such a cell line producing UNG2 under it own
cell cycle-regulated promoter (Kavli et al, 2002) and under an
inducible promoter (Akbari et al, 2004). However, induction
of high UNG2 expression results in an increased fraction of
cells in the S/G2 stage of the cell cycle compared with the
control cell line (data not shown). This underscores that
tightly regulated expression of UNG2 is of vital importance
for the cells.
In vitro phosphorylation of UNG2 by cyclin-dependent
kinases stimulates UNG2 catalytic activity
Both their regulation in the cell cycle and their position
immediately N-terminus to prolines in the primary amino-
acid sequence (Figure 2D) indicate that the N-terminal UNG2
phosphorylation sites may be targeted by cyclin-dependent
kinases (CDKs). To investigate this in more detail, we ﬁrst
reprobed 2D western blots of UNG2 immunoprecipitates
using CDK1 and CDK2 antibodies. Of these, CDK2 was clearly
identiﬁed (Figure 5A). We then tested the effect of the CDK
inhibitors olomoucine and roscovitine on the phosphoryla-
tion pattern of UNG2. However, since this treatment also
affected the distribution of cells in the cell cycle, the results
could not be interpreted in terms of direct effects of indivi-
dual CDKs on UNG2 activity (data not shown). As an alter-
native approach, we investigated the ability of four active
CDK/cyclin pairs to phosphorylate UNG2 in vitro. Of these,
CDK4/cyclin D1/D3 is active in G1, CDK2/cyclin E in late G1/
S, CDK2/cyclin A in late S/G2 and CDK1/cyclin B in M. When
UNG2 was subjected to in vitro phosphorylation by either of
these sets of CDK/cyclins, multiple phosphorylated forms of
UNG2 were observed (Figure 5B). Mass spectrometry ana-
lyses revealed that the ‘early’ CDK4/cyclin D and CDK2/
cyclin E kinases were able to phosphorylate all three UNG2
Ser/Thr residues observed in vivo (only CDK2/cyclin E
shown). Of these, only S64 was phosphorylated by the
‘late’ CDK2/cyclin A and CDK1/cyclin B kinases (Figure 5B,
upper panels) in agreement with the accumulation of this
phosphorylation in G2 (Figure 3B). In addition, (unspeciﬁc)
phosphorylation by all kinases was observed at S12 and S14.
To avoid interference from phosphorylations at these resi-
dues, an S12A/S14A mutant was puriﬁed and subjected to in
vitro phosphorylation by the above kinases. This yielded the
same pattern of phosphorylations as in WT UNG2, except at
the mutated sites. PCNA was also added in parallel reactions
since PCNA has been shown to act as a connector to
target CDK/cyclins to speciﬁc DNA replication proteins
(Koundrioukoff et al, 2000). No change in the phosphoryla-
tion pattern was observed in the presence of PCNA (data not
shown). Although differential quantiﬁcation of the phosphor-
ylations was not possible by our analyses, the results indicate
an overlapping function of the various CDK/cyclins in the cell
cycle regulation of UNG2.
As shown in Figure 5C, phosphorylation by each of the
kinases mediated a signiﬁcant (20–30%) increase in UNG2
activity. Although these analyses did not allow quantiﬁcation
of the precise activity of each of the true UNG2 phosphoforms
as observed in vivo, the results clearly demonstrate that
phosphorylation of the N-terminal regulatory domain stimu-
lates the catalytic activity of UNG2, in support of the results
from phosphomimicking mutants.
Finally, the activity increase observed in the phosphomi-
micking mutants was corroborated by phosphatase treatment
of HeLa cell extracts. When total extracts from cells in G1/S
phase were subjected to dephosphorylation using calf intes-
tine phosphatase, the total UDG activity was reduced by
about 25% (Figure 5D). In this extract, the p-S23 form of
UNG2 is the quantitatively dominating form (Figure 3B; 0h)
and the major part of the activity reduction is likely attributed
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reduction in UNG2 p-S23 activity is likely higher, since the
cell extracts also contain appreciable amounts of non-phos-
phorylated UNG1, which would remain unaffected by the
phosphatase treatment. In summary, the in vitro phosphor-
ylation and the phosphatase experiments strongly support
that UNG2 phosphomimicking mutants are valid models
for studying the functional consequences of in vivo UNG
phosphorylation.
Discussion
Accumulating evidence suggests that phosphorylation of
DNA base excision repair proteins plays a key role in ﬁne
tuning of DNA repair as well as in coordination of DNA repair
with other cellular processes such as DNA replication (re-
viewed in Fan and Wilson, 2005). However, the precise
phosphoforms of the proteins existing in vivo, the kinases
involved and the functional implications of the phosphoryla-
tions in BER, remain poorly understood for most BER
proteins.
Here, we present the ﬁrst precise identiﬁcation of three cell
cycle-regulated phosphoforms of UNG2, and provide evi-
dence that these may be generated by distinct CDK/cyclins.
Moreover, the phosphorylations regulate cellular turnover of
the UNG2 protein, association with RPA and modulates
catalytic activity. Ubiquitin-dependent breakdown of UNG2
observed by Fischer et al (2004) and their ﬁnding that
breakdown is inhibited by the CDK inhibitor roscovitine is
corroborated by our results. We furthermore ﬁnd that the
maximum level of apparently mono-ubiquitinylated and
triple-phosphorylated form of UNG2 occurs in G2, concomi-
tantly with the lowest level of total UNG2. This, the migration
in 2D gels of ubiquitinylated UNG2 relative to triple-phos-
phorylated UNG2, and the increased cellular accumulation of
the S64A-containing mutants in the putative phosphodegron,
strongly indicate that the triple-phosphorylated protein
serves as a precursor for ubiquitinylation and breakdown in
late S/G2. Interestingly, very recent work from the laboratory
of Primo Scha ¨r has demonstrated that TDG, another member
of the UDG superfamily, is downregulated upon entry of the S
phase and upregulated in G2 (Hardeland et al, 2007). This
inverse regulation of UNG2 and TDG implies that the two
uracil-DNA glycosylases have non-redundant functions that
must be coordinated through the cell cycle. Apparently, the
presence of TDG in the S phase is incompatible with cell cycle
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potential explanation for this is the exceptional strong bind-
ing of TDG to product AP sites (Waters et al, 1999) that could
obstruct replication. It is less clear however, why UNG2 is
degraded in late S/G2, since deamination of cytosine to uracil
also is likely to occur during G2. One clue might come from
our recent ﬁndings that removal of uracil at Xenopus centro-
meres apparently mediates loading of CENP-A, a central
component in kinetochore formation (Zeitlin et al, 2005).
Although speculative, it is possible that a strictly regulated
level of UNG2, or speciﬁc phosphoforms of UNG2, may be
necessary to conﬁne uracil excision to centromere regions
during G2. Alternatively, the cellular level of UNG2 is reduced
during G2 to allow temporary persistence of deaminated
cytosines serving as initiator sites for CENP-A loading.
The increase in the UNG2 catalytic activity subsequent to
phosphorylation by CDK/cyclins may be of special functional
importance, since UNG2 attached to the replication machin-
ery should be able to cope with the speed of the replication
fork to efﬁciently recognise and remove uracils. Association
of UNG2 to PCNA (Otterlei et al, 1999) and the doubling of
the catalytic turnover of monophosphorylated relative to WT
UNG2 against dsDNA likely support rapid removal of mis-
incorporated uracil (U:A) from the newly synthesised strand.
Conversely, virtually nothing is known about uracil proces-
sing in the single-stranded DNA region in front of the
replicative polymerase. Deamination of cytosine occurs 200-
to 300-fold faster in ssDNA than in dsDNA (Lindahl, 1993),
and likely poses a signiﬁcant mutagenic threat when occur-
ring immediately in front of the replicative polymerases.
Increased binding of monophosphorylated (p-S23) UNG2 to
RPA during S phase, concomitant with markedly (three-fold)
increased catalytic turnover against single-stranded uracils
conform with a role of UNG2 in prereplicative removal of
uracil. It is less clear if the di- and triphosphorylated forms of
UNG2 possess additional functional characteristics that aid
replicative uracil removal. Rather, we hypothesise that the
main function of these phosphorylations is to create a phos-
phodegron that initiates ubiquitinylation. This is also sup-
ported by the reduced binding of the fully phosphorylated
UNG2 to RPA, that likely release UNG2 and facilitates recog-
nition by an E3 ubiquitin ligase. It can furthermore not be
excluded that ubiquitinylation may be regulated by additional
factors than mere phosphorylation status. One possibility is
that fully phosphorylated UNG2 released from chromatin
upon termination of replication forks is targeted for ubiqui-
tinylation. Alternatively, PCNA may serve as an adaptor for
UNG2 ubiquitinylation, since the PCNA-binding capacity of
UNG2 is retained in the phosphomimicking mutants. PCNA-
dependent ubiquitinylation and proteolysis were recently
reported for the Xenopus replication licensing factor Cdt1
(Arias and Walter, 2006). Notably, Cdt1 binds to PCNAvia the
same conserved PCNA-binding motif as in UNG2. Work is
now in progress to identify the E3 ligase responsible for
UNG2 ubiquitinylation. This work may shed new light
upon the mechanisms underlying UNG2 protein turnover
during the cell cycle, and the potential consequences of
dysregulated turnover.
In activated B cells, excision of AID-deaminated cytosines
from the template strand of the replication fork was recently
proposed to act as a speciﬁc trigger of translesion synthesis (Di
Noia et al, 2006). This could explain the mutagenic outcome of
uracil excision rather than faithful repair. However, it is not
clear why such translesion synthesis across AP sites should be
triggered in activated B cells and not in other replicating cells.
Given the results presented here, the role of distinct functional
modiﬁcations of UNG2 in activated B cells should provide an
attractive area for future investigations.
Materials and methods
Reagents
Primary antibodies were PU059 recognising the catalytic domain of
UNG2 (0.5mg/ml), anti-RPA (Abcam ab2175), anti-PCNA (Abcam
ab29), anti-actin (Abcam ab8226), anti-ubiquitin (Santa Cruz
sc-8017), anti-CDK1 (Santa Cruz sc-747), anti-CDK2 (Santa Cruz
sc-748) and anti-GFP (prepared in-house). Secondary antibodies
were swine anti-rabbit, HRP (Dako Chemicals), rabbit anti-mouse,
HRP (Dako Chemicals), Cy3 anti-mouse/Cy5 anti-rabbit (GE
Healthcare). The expression vector pET11d-tRPA encoding the
trimeric RPA complex was kindly provided by Professor Marc Wold
at The University of Iowa. Expression and puriﬁcation were
essentially as described (Henricksen et al, 1994).
Cell culture, synchronisation and preparation of extracts
HeLa cells were grown in suspension in HEPES-buffered DMEM,
10% FCS, 0.03% glutamine, 0.1mg/ml gentamicin and 2.3mg/ml
fungizone. Nuclear extracts were prepared from 2.5 10
8 cells.
After pelleting and washing in PBS, cells were resuspended in ﬁve
volumes of hypotonic buffer (10mM HEPES pH 7.9, 10mM KCl,
1.5mM MgCl2, 1mM DTT, Complete
s EDTA-free protease inhibitors
(Roche) and phosphatase inhibitor cocktails 1 and 2 (Sigma) and
incubated for 10min on ice. Cells were lysed by 15 strokes in a
Kontes glass homogeniser (B-type pestle) and nuclei pelleted by
centrifugation at 680g for 5min. Nuclear pellets were resuspended
in two volumes of extraction buffer (10mM Tris–HCl pH 7.8,
200mM KCl, 20% glycerol, 0.25% NP40, 1mM DTT and protease
and phosphatase inhibitors) and proteins were extracted at 41C for
2h. Finally, extracts were clariﬁed at 16000g for 20min. HeLa cells
were synchronised by the double thymidine block essentially as
described (Richardson et al, 2000). Veriﬁcation of cell cycle stage
was performed by standard ﬂow cytometry. At deﬁned time points
post-release, cells were washed twice in ice-cold PBS, resuspended
in two volumes of extraction buffer, and proteins were extracted
and clariﬁed as above. When stated, the pellets were further
extracted by sonication in a buffer containing 400mM KCl, and
clariﬁed as above. UNG
 /  lymphoblastoid cells were grown, and
total extracts thereof prepared as described (Akbari et al, 2004). All
extracts were snap-frozen in liquid N2 and stored at  801C prior to
use. For analysis of UDG activity subsequent to dephosphorylation,
HeLa G1/S-phase extract (5mg protein) was treated with 40U of calf
intestine phosphatase for 45min at 371C prior to analysis.
Immunoprecipitation, electrophoresis and western analysis
UNG2 was isolated using polyclonal PU059 that recognises the
UNG1/2 common catalytic domain. PU059 (20mg) was covalently
coupled to 100ml magnetic Dynabeads
s Protein-A (Dynal, Norway)
according to the manufacturer’s instructions. After incubation with
protein extract for 4h at 41C, the beads were thoroughly washed
and proteins were eluted overnight in Destreak rehydration solution
(GE Healthcare), 1% IPG buffer for 2D electrophoresis. For
dephosphorylation, the beads were treated with 40U of calf
intestinal phosphatase (New England Biolabs) prior to elution of
bound proteins.
1D PAGE was performed in 10% NuPage Novex Bis-Tris gels
using MOPS run buffer. For 2D PAGE, proteins were focused in 7–11
IPG NL strips at 201C and 50mA (18cm for silver-stained gels and
7cm for gels prior to western analysis) in the IPGphor II unit (GE
Healthcare). Strips were equilibrated in DTT and iodoacetamide
prior to second dimension SDS–PAGE. Gels were either electro-
blotted on PVDF (ImmobilonTM; Millipore) or Hybond LFP (GE
Healthcare) or silver stained. Membranes were blocked for 1h in
PBS, 0.1% Tween (PBST), 5% fat-free dry milk and incubated in
primary antibody for 1h in blocking buffer. After 3 10min
washing in PBST, membranes were further incubated for 1h in
secondary HRP-conjugated antibodies in PBST, washed 3 10min
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visualised using Kodak Image station 2000R. Membranes incubated
with Cy3/Cy5-labelled secondary antibodies were visualised using a
Typhoon Trio imager (GE Healthcare).
In-gel digestion and mass spectrometric analysis
Silver-stained spots were excised from gels and in-gel digested with
trypsin as described (Shevchenko et al, 1996). Dried peptides were
resuspended in 10ml of 0.5% acetic acid, 0.02% heptaﬂuorobutyric
acid, desalted as described (Rappsilber et al, 2003) and matrix
(0.3g/l a-cyano-4-hyroxycinnamic acid (CHCA) was added in
EtOH:acetone (2:1) on an anchor chip plate. Peptide ﬁngerprints
were acquired with a Reﬂex IV MALDI-TOF mass spectrometer
(Bruker Daltonics) in reﬂectron mode. The human portion of the
NCBI database was interrogated using the Mascot software (Matrix
Science).
For MS/MS analysis, tryptic peptides were prepared as above. To
reduce the complexity of the collision-induced fragmentation
pattern, the C-terminal lysine in the phosphopeptide encompassing
aa 20–49 was chemically modiﬁed (Peters et al, 2001). Peptides
were incubated in 0.4M 2-methoxy-4,5-dihydro-1H-imidazole pH
10.5 for 3h at 551C, the reaction was quenched by 5% (v/v) FA and
desalted using in-house-prepared PorosR2 (Applied Biosystems)
micro-columns. Peptides were directly eluted on MALDI plates with
2.5-dihydroxybenzoic acid (DHB) in 50% acetonitrile, 1% phos-
phoric acid (Stensballe and Jensen, 2004). MS/MS spectra were
acquired using a Q-TOF Ultima MALDI (Waters Micromass) mass
spectrometer, equipped with an in-source camera and raw data
were manually processed.
In vitro phosphorylations were identiﬁed by nano LC-MS/MS
using gradient elution from an in-house-prepared ReproSil-Pur C18-
AQ column (75mm 50mm, 3mm particle size) (Dr Maisch GmbH).
Injection volume was 5ml, and samples were desalted on a C18
PepMap100 Nano-Precolumn (300mm 1mm, 5mm particle size)
(LC Packings). Eluted peptides were analysed online by a QStar XL
(Applied Biosystems) mass spectrometer, using a PicoTip Emitter
needle and applied ionising voltage of 2400V. Only ions of charge
states þ2, þ3 and þ4 were analysed in MS/MS mode. MS/MS
data were subsequently analysed by Mascot software (Matrix
Science).
UNG2 mutants, co-immunoprecipitation, in vitro
phosphorylation and UDG activity assays
Mutations in pET28a-UNG2 (Scaramozzino et al, 2003) were
introduced by Quick-change site-directed mutagenesis (Stratagene).
His-tagged WT UNG2 and mutants were expressed in E. coli BL21-
Codon plus
s (DE3)-RIPL (Stratagene). LB cultures (1l) were grown
to OD 0.6 at 371C, induced by 1mM IPTG and UNG2 expressed at
161C overnight. Cells were sonicated on ice in the presence of 1mg/
ml lysozyme and Complete (Roche) protease inhibitors. Nucleic
acids were precipitated with 0.4% protamine sulphate. His-tagged
UNG2 mutants were puriﬁed by TALON Superﬂow Resin (Clontech)
and dialysed against UNG buffer containing 20mM Tris–HCl pH 7.5,
60mM NaCl, 1mM EDTA and 1mM DTT. After addition of glycerol
to 50%, proteins were snap-frozen in liquid N2 and stored as
aliquots at  801C. Initial protein concentration was measured using
the Bio-Rad assay using BSA as a standard. To allow precise relative
quantiﬁcation, all puriﬁed UNG2 proteins were subjected to
polyacrylamide gel electrophoresis (six gels), stained with Simply-
Blue (Invitrogen), and subjected to densitometric analysis. For
co-immunoprecipitation analysis, 100ng UNG2 WT or phosphomi-
micking mutants were incubated with 1mg UNG
 /  lympho-
blastoid cell extract for 2h at 41C and complexes were immuno-
precipitated using PU059-coupled Dynabeads. For precipitation of
PCNA, extracts were treated with Omnicleave endonuclease
(Epicentre) to release PCNA from chromatin. After washing in
3 0.5ml 10mM Tris pH 7.8, bound proteins were eluted in 1 
LDS loading buffer supplemented with 50mM DTTand separated in
10% NuPage Novex Bis-Tris gels using MOPS run buffer and
subjected to western analysis as described above. UNG2 proteins
were in vitro phosphorylated with CDK4/cyclin D1 and CDK4/
cyclin D3 (Cell Signalling), CDK2/cyclin A and CDK2/cyclin B
(Upstate) and CDK2/cyclin E (BIOMOL International) according to
the manufacturer’s instructions. UDG activity of the UNG2 proteins
was assayed against [
3H]dUMP-containing calf thymus DNA (U:A)
as described (Kavli et al, 2002). For enzyme kinetic analyses, UNG2
proteins were analysed in the presence of [
3H]dUMP-containing ds
(U:A) at concentrations ranging from 0.02 to 1.8mM, and single-
stranded [
3H]dUMP-containing DNA at concentrations ranging from
0.1 to 8.4mM. When stated, 0.85pmol of RPA trimer was added to
the reactions. Enzyme kinetic parameters were calculated using the
Enzpack for Windows version 1.4 software package (Biosoft) using
the method of Wilkinson.
Mammalian expression constructs and confocal microscopy
pUNG2-EYFP and pNLS-ECFP-PCNA were published previously
(Kavli et al, 2005). Site-speciﬁc mutations were introduced as above
and veriﬁed by DNA sequencing. HeLa cells were transfected using
FuGENE 6 (Roche) according to the manufacturer’s protocol.
Fluorescent images (1mm thickness) of transfected, freely cycling
cells were recorded 24h post-transfection using a Zeiss LSM 510
laser scanning microscope equipped with a Plan-Apochromate
63 /1.4 oil immersion objective.
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